Daneng Li
@DanengLi
Followers
2K
Following
1K
Media
1
Statuses
178
GI Medical Oncologist @CityofHope. Hepatobiliary & NET Cancers. Tweets are my own opinions. RTs are not endorsements.
Los Angeles, CA
Joined May 2020
Congrats Dani and team. Wonderful work highlighting this area of need. @OncJournal @cityofhope
PARP Inhibitors in Gastric Cancer: Unlocking Precision Oncology https://t.co/kdwhy6X7Lb
#oncologist @DanengLi
0
0
2
Excited to share our recent publication! It's been a pleasure working with our amazing residents during their hem/onc rotations.# frontier in Oncology #ctDNA @DanengLi @gagan_brar24
0
2
16
Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI cancer care. (CME). 👉 FREE HCP Registration (USE
2
14
16
Honored to moderate this amazing session with wonderful colleagues @lisayentwin @drjasonstarr @AGangiMD and Sandy B from Penn. @NANETS1 @LACNETS #NANETS24
Thanks @NANETS1 for the invitation to engage in a unique & insightful panel discussion on common challenges in patient-provider and provider-provider communication. #NANETS24
2
2
28
Thanks @PoHienEar. It has been amazing Co-chairing this years symposium with you. Honored to moderate this great session @cityofhope @COHMedOnc #NANETS24
Addressing an important topic for our patients! @DanengLi @lisayentwin @AGangiMD @drjasonstarr Amy Allen thank you!!!🙏 #NANETS2024
0
4
16
The November issue of ONCOLOGY features a wide range of articles from those focused on survivorship, multiple myeloma and pleural effusion, and gender equity. Read the full issue here: https://t.co/6JdsY303RI
@DrJulieVose @johndiazmd @TomBmt133 @DrAmyComander @DanengLi
0
3
5
Looks like an amazing presentation @lisayentwin @LACNETS Congrats. Honored to be part of the journey with you and your team.
LACNETS Director of Programs & Outreach, Lisa Yen, is at the 2024 INCA Global NET Summit in Segovia where she presented NET VITALS as an example of best practices & challenges in working with the medical community. Check out NET VITALS here: https://t.co/8YpA8YWeV7
@netcancerday
0
0
9
📢Please join this week's educational webinar: "Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) for Cholangiocarcinoma Patients with Peritoneal Metastases" with Dr. Daneng Li and Dr. Mustafa Raoof from @cityofhope in Duarte, CA. ⬆️Up to 20% of biliary tract cancer
0
6
12
Out now, the Methods Full article: IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma https://t.co/1P79HLIQJs. 1st global study with Atezo/bev as comparator. Hopeful for #HCC pts. @cityofhope @COHMedOnc
tandfonline.com
Atezolizumab plus bevacizumab is a standard of care, first-line therapy for advanced hepatocellular carcinoma (HCC). Myeloid and T regulatory cells are key immunosuppressive cell types within the h...
4
6
21
Patient preferences should be considered when making shared decisions about cancer therapy. In this analysis, @cityofhope researchers explore outcome prioritization among older adults with cancer. #OpenAccess link: https://t.co/OSKFwF4nPn
@EnriqueSoto8
@OncoAlert
0
6
7
Happy to have this study published with @EnriqueSoto8. Patient preferences matter among older adults with cancer receiving treatment. Hope we are continuing to make Arti proud. @JournalCancer @cityofhope @COHMedOnc @WilliamDale_MD @vani_katheria @SunCanlan @minasedrakmd #gerionc
Our manuscript on the priorities of older patients regarding outcomes in cancer care is out in @JournalCancer. Here , we studied which outcomes were more important for older adults starting chemo. #gerionc @cityofhope @ConquerCancerFd FREE here ⬇️ https://t.co/qrz5icQ1wL
0
3
13
Happy to share ongoing phase I dose escalation data for CF33-hNIS @AACR #AACR24. Excellent safety and encouraging early efficacy even seen at low dose levels in refractory tumor types such as #cholangiocarcinoma #bileductcancer @cityofhope @TeamImugene @COHMedOnc @CityofHopeSurg
American Association for #Cancer Research (@AACR) Poster Presentation: "#Oncolytic virus CF33-hNIS for the treatment of advanced cancer" Presented by Dr. Daneng Li from the @cityofhope National Comprehensive Cancer Centre Abstract Presentation Number: CT182 Session Date and
1
4
29
Ipi/Nivo meets OS endpoint for 1st line #HCC. Will be interesting to see the data given mix of Len or Sor comparator arm. Good news for pts that prior AA in the second line setting will likely be kept.
news.bms.com
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb...
0
4
25
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space. #gicsm #GI24 | @ASCO @jgong15 @DanengLi @CedarsSinai @cityofhope
https://t.co/wIg48iqQbS
cancernetwork.com
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
0
7
10
Written by @vickyyyf. Featuring research by Drs Riccardo Lencioni from @Unipisa, Kuang Ming from Sun Yat-sen University, @DanengLi from @CityofHope, and Jia-Yi Wu from Fujian Provincial Hospital.
0
1
2
Happening tonight, @jgong15 and @DanengLi with co-host a Twitter Spaces focused on the most important data from #GI24, don't miss it! @CedarsSinai @cityofhope
0
4
13
As #GI24 kicks off this weekend, mark your calendars for an exciting recap of the conference with hosts @jgong15 @DanengLi on Thursday 1/25 at 5:30 pm ET! #gicsm | @ASCO @CedarsSinai @cityofhope
0
4
6
Tune in to our exciting Spaces after #GI24 with @jgong15 and @DanengLi to discuss the most pertinent presentations from the conference. @ASCO @cityofhope @CSCancerCenter
0
3
11
Honored to lead the GI cohorts from COSMIC-021. Lack of activity in gastric/GE junction tumor. Signal in #HCC that led to COSMIC312. More work needed @montypal @COHMedOnc @cityofhope Cabozantinib plus atezolizumab in previously untreated advanced hepato...
0
2
13
Look forward to this upcoming exciting #SITC program to discuss the next generation of immunotherapy in GI cancers. Come join us. @cityofhope @COHMedOnc @jgong15 @MarkYarchoan @DrArsenOsipov
Looking forward to an exciting #SITC program Advances in Cancer Immunotherapy: A Focus on Gastrointestinal Cancers co-chaired by our very own @DrArsenOsipov Suwicha Limvorasak @CSCancerCenter December 4 register at https://t.co/fJXuVvnj7c
@MarkYarchoan @DanengLi @MikeFooteMD
0
5
15